1Rhian Clissold,Steve Clissold.Insulin glargine in the management of diabetes mellitus:an evidence-based assessment of its clinical efficacy and economic value[J].Core Evidence,2007,2(2):90.
2S.luzio,G.dunseath,R.Peter etc.Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.Diabetologia,2006,49:1163.
3J.A.Ray,W.J.Valentine,S.Rose,etc.Insulin therapy in type 2 diabetes patients failing oral agents:cost-effectiveness of biphasic insulin aspart 70/30 vs.insulin glargine in the US[J].Diabetes,Obesity and Metabolism,2007,9:103.
7A.Mori,T.Sako,P.Lee,etc.Comparison of time-action profiles of insulin Glargine and NPH insulin in normal and diabetic dogs.Vet Res Commun,2008,32:563.
8Reinhard G,Bretzei,Sabine Arnolds,etc.A Direct Efficacy and Safety Comparison of Insulin Aspart,Human Soluble Insulin,and Human Premix Insulin(70/30) in Patients With Type 2 Diabetes.Diabetes Care,2004,27(5):1023.
3Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care, 2005,28:1231-1239.
4The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus.Diabetes Care, 2003,26:3160-3167.
5American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care, 2005,28 : 1245-1249.
6Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes,1970,19:644-655.
7Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia, 1972,8:342-348.
8Freckmann G, Kalatz B, Pfeiffer B, et al. Recent advances in continuous glucose monitoring. Exp Clin Endocrinol Diabetes,2001,109 : S347-357.
9Selam JL. How to measure glycemic instability? Diabetes Metab,2000,26 : 148-151.
10Guerci B. Asymptomatic glycemic instability: how to measure it and which clinical applications? Diabetes Metab, 2003,29:179-188.
4Esposito K, Ciotola M, Maiorino M I, et al. Addition of neu- tral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glyeemic con- trol: a randomized trial[J]. Ann Intern Med, 2008, 149 (8) : 531.
5Janka H U, Plewe G, Busch K. Combination of oral antidia- betic agents with basal insulin veins premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus[J ]. ] Am Geriatr Soc, 2007, 55(2) : 182.
